Zacks Research Raises Earnings Estimates for DENTSPLY SIRONA

Key Points

• Zacks Research raised its Q3 2026 EPS estimate for DENTSPLY SIRONA to $0.37 from $0.36, while keeping a Hold rating on the stock. The consensus full-year earnings estimate remains $1.42 per share.
• Analyst sentiment is mixed, with a MarketBeat consensus rating of Hold and an average price target of $13.82. Recent moves included price target increases from Baird and Bank of America, but Citigroup initiated coverage with a Sell rating.
• Recent company performance was mixed: DENTSPLY SIRONA reported Q1 EPS of $0.27, missing estimates by $0.01, though revenue came in above expectations at $880 million. The company also reaffirmed FY 2026 guidance of $1.40 to $1.50 EPS.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) - Zacks Research raised their Q3 2026 earnings per share estimates for shares of DENTSPLY SIRONA in a note issued to investors on Tuesday, May 26th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $0.37 per share for the quarter, up from their previous estimate of $0.36. Zacks Research has a "Hold" rating on the stock. The consensus estimate for DENTSPLY SIRONA's current full-year earnings is $1.42 per share.

Other equities analysts also recently issued research reports about the company. Robert W. Baird upped their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a "neutral" rating in a research report on Friday, February 27th. Weiss Ratings downgraded DENTSPLY SIRONA from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, May 6th. Citigroup began coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a "sell" rating and a $10.00 price target for the company. UBS Group decreased their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Thursday, May 7th. Finally, Bank of America upgraded DENTSPLY SIRONA from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $13.82.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock opened at $10.00 on Thursday. The stock's fifty day moving average is $11.33 and its two-hundred day moving average is $11.76. The company has a market capitalization of $2.00 billion, a PE ratio of -3.17, a price-to-earnings-growth ratio of 1.19 and a beta of 0.93. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA has a 52 week low of $9.40 and a 52 week high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The business had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The business's revenue was up .1% compared to the same quarter last year. During the same period last year, the company earned $0.43 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS.

Institutional Trading of DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE increased its position in shares of DENTSPLY SIRONA by 18.3% in the first quarter. Bank of America Corp DE now owns 2,432,457 shares of the medical instruments supplier's stock valued at $28,217,000 after buying an additional 375,994 shares in the last quarter. RBF Capital LLC increased its position in shares of DENTSPLY SIRONA by 2.5% in the first quarter. RBF Capital LLC now owns 205,000 shares of the medical instruments supplier's stock valued at $2,378,000 after buying an additional 5,000 shares in the last quarter. Arkadios Wealth Advisors purchased a new stake in shares of DENTSPLY SIRONA in the first quarter valued at approximately $870,000. California State Teachers Retirement System increased its position in shares of DENTSPLY SIRONA by 24.0% in the first quarter. California State Teachers Retirement System now owns 232,031 shares of the medical instruments supplier's stock valued at $2,692,000 after buying an additional 44,918 shares in the last quarter. Finally, Royal Bank of Canada increased its position in shares of DENTSPLY SIRONA by 137.7% in the first quarter. Royal Bank of Canada now owns 256,701 shares of the medical instruments supplier's stock valued at $2,978,000 after buying an additional 148,702 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director James D. Forbes acquired 5,000 shares of the business's stock in a transaction dated Monday, March 9th. The stock was acquired at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company's stock, valued at $124,800. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gregory T. Lucier acquired 15,000 shares of the business's stock in a transaction dated Monday, March 9th. The stock was acquired at an average price of $12.45 per share, with a total value of $186,750.00. Following the completion of the transaction, the director directly owned 65,000 shares of the company's stock, valued at approximately $809,250. This represents a 30.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 70,000 shares of company stock worth $956,437. 0.50% of the stock is owned by company insiders.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: DENTSPLY SIRONA announced it is expanding its U.S. distribution network through a broader partnership with Nashville Dental, Inc., which should improve access to its digital dentistry solutions in key regional markets and may help sales momentum. Article Title
• Neutral Sentiment: The company presented at the Stifel Jaws & Paws Conference 2026, which can keep investors focused on management’s strategic outlook, but the transcript itself does not indicate a major new catalyst. Article Title
• Negative Sentiment: Zacks Research cut earnings estimates across several future periods, including FY2026, FY2027, and FY2028, while keeping a Hold rating. Lower profit expectations can weigh on the shares because they suggest slower earnings growth than previously expected.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.